Gyre Therapeutics, Inc.
GYRE
$7.02
-$0.63-8.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.59M | 107.27M | 102.19M | 100.64M | 105.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.59M | 107.27M | 102.19M | 100.64M | 105.76M |
| Cost of Revenue | 5.42M | 4.85M | 4.18M | 3.80M | 3.88M |
| Gross Profit | 111.17M | 102.42M | 98.01M | 96.84M | 101.87M |
| SG&A Expenses | 85.98M | 77.79M | 75.66M | 73.48M | 73.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.10M | 95.23M | 92.85M | 90.21M | 89.53M |
| Operating Income | 11.49M | 12.03M | 9.34M | 10.43M | 16.23M |
| Income Before Tax | 14.44M | 15.27M | 11.58M | 15.37M | 23.22M |
| Income Tax Expenses | 4.56M | 3.46M | 2.84M | 3.68M | 5.32M |
| Earnings from Continuing Operations | 9.88 | 11.82 | 8.74 | 11.70 | 17.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.85M | -5.16M | -4.57M | -4.45M | -5.81M |
| Net Income | 5.03M | 6.65M | 4.17M | 7.25M | 12.09M |
| EBIT | 11.49M | 12.03M | 9.34M | 10.43M | 16.23M |
| EBITDA | 14.01M | 14.36M | 11.46M | 12.14M | 17.82M |
| EPS Basic | 0.06 | 0.07 | 0.05 | 0.08 | 0.14 |
| Normalized Basic EPS | 0.04 | 0.05 | 0.03 | 0.06 | 0.10 |
| EPS Diluted | 0.02 | 0.04 | 0.02 | 0.02 | 0.05 |
| Normalized Diluted EPS | 0.03 | 0.04 | 0.03 | 0.05 | 0.08 |
| Average Basic Shares Outstanding | 357.55M | 352.34M | 347.14M | 343.52M | 340.36M |
| Average Diluted Shares Outstanding | 399.80M | 394.60M | 393.27M | 392.77M | 393.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |